Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 401–500 of 1,001
Mahadevappa, R., Neves, H., Yuen, S. M., Jameel, M., Bai, Y., Yuen, H., Zhang, S., Zhu, Y., Lin, Y., & Kwok, H. F. (2018) · Cancers · doi:10.3390/cancers10090282 · Cited by 48
“Depletion of some of these licensing factors, in vitro, is known to reduce cell proliferation as well as induce programmed cell death [10].”
BackgroundLi, D., Lin, C., Li, N., Du, Y., Yang, C., Bai, Y., Feng, Z., Chen, S., Wu, R., Song, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.051 · Cited by 52
“In addition, some transcription factors are overactive in human cancer, which makes them targets for the development of anticancer drugs [57].”
BackgroundPRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling
Weber, S., Maaß, F., Schuemann, M., Krause, E., Suske, G., & Bauer, U. (2009) · Genes & Development · doi:10.1101/gad.489409 · Cited by 53
RetractedDubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0348 · Cited by 47
Alonso, N., Guillen, R., Chambers, J. W., & Leng, F. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv069 · Cited by 47
“Abnormal expression and/or aberrant regulation of certain transcription factors are involved in human oncogenesis (7), and tumor proliferation and malignancy (8,9).”
BackgroundEmerging Roles of TRIM8 in Health and Disease
Marzano, F., Guerrini, L., Pesole, G., Sbisà, E., & Tullo, A. (2021) · Cells · doi:10.3390/cells10030561 · Cited by 50
Systematic characterization of protein-DNA interactions
Xie, Z., Hu, S., Qian, J. X., Blackshaw, S., & Zhu, H. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0617-y · Cited by 54
“Sequence-specific protein-DNA interactions (PDIs) play a central role in regulating gene transcription; mutations in DNA-binding proteins such as transcription factors (TFs) can often cause diseases and cancer in humans [1].”
BackgroundGuo, Y., Partch, C. L., Key, J., Card, P. B., Pashkov, V., Patel, A., Bruick, R. K., Wurdak, H., & Gardner, K. H. (2013) · ACS Chemical Biology · doi:10.1021/cb300604u · Cited by 47
Krüppel-Like Factor 12 Promotes Colorectal Cancer Growth through Early Growth Response Protein 1
Kim, S.-H., Park, Y., Cho, S.-N., Margalit, O., Wang, D., & DuBois, R. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159899 · Cited by 46
“Transcription factors that regulate gene expression and certain signaling pathways during carcinogenesis are potential therapeutic targets [2], although technical difficulties usually preclude targeting them directly [3,4].”
BackgroundMatsuda, T. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00887 · Cited by 54
Shah, N. G., Trivedi, T. I., Tankshali, R. A., Goswami, J., Jetly, D., Kobawala, T. P., Shukla, S. N., Shah, P. M., & Verma, R. J. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100307 · Cited by 50
Chromosomal translocation products engender new intracellular therapeutic technologies
Rabbitts, T. H., & Stocks, M. (2003) · Nature Medicine · doi:10.1038/nm0403-383 · Cited by 47
Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent
Nguyen, T. M., & Lee, C. H. (2019) · Molecules · doi:10.3390/molecules24203659 · Cited by 47
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 46
Ginsberg, M. D., Czeko, E., Müller, P., Ren, Z. J., Chen, X., & Darnell, J. E., Jr. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00613-07 · Cited by 45
“Latent transcription factors are often the ultimate agents of carcinogenesis when signaling pathways are dysregulated (8).”
BackgroundRoy, N. V., Preter, K. D., Hoebeeck, J., Maerken, T. V., Pattyn, F., Mestdagh, P., Vermeulen, J., Vandesompele, J., & Speleman, F. (2009) · Genome Medicine · doi:10.1186/gm74 · Cited by 51
“These efforts have not yet resulted in a mainstream anticancer therapy, which may in part be explained by difficulties associated with selective pharmaco logical inhibition of nuclear transcription factors [106], but various strategies aimed at counteracting MYCN activity are actively being pursued.”
Liu, Y., Du, J., Choi, J., Chen, K., Hou, S., Yan, M., Lin, W., Chen, K. S., Ro, T., Lipshutz, G. S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507546 · Cited by 45
Kamitani, S., Togi, S., Ikeda, O., Nakasuji, M., Sakauchi, A., Sekine, Y., Muromoto, R., Oritani, K., & Matsuda, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003243 · Cited by 48
A Linear Model for Transcription Factor Binding Affinity Prediction in Protein Binding Microarrays
Annala, M., Laurila, K., Lähdesmäki, H. J., & Nykter, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020059 · Cited by 47
Douglas, W. G., Tracy, E., Tan, D., Yu, J., Hicks, W. L., Rigual, N., Loree, T. R., Wang, Y., & Baumann, H. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.585.2.10 · Cited by 46
Elumalai, N., Berg, A., Rubner, S., Blechschmidt, L., Song, C., Natarajan, K., Matysik, J., & Berg, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-00920-3 · Cited by 44
“Binding of catechol bisphosphate (1) to the STAT5b SH2 domain.”
Butler, M. S., Roshan‐Moniri, M., Hsing, M., Lau, D., Kim, A., Yen, P., Mroczek, M., Nouri, M., Lien, S. C., Axerio-Cilies, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17124 · Cited by 47
“However, in the context of the cellular milieu, transcription factor binding to DNA is malleable and susceptible to chemical perturbations [42, 43].”
BackgroundAlong the Central Dogma—Controlling Gene Expression with Small Molecules
Schneider‐Poetsch, T., & Yoshida, M. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033923 · Cited by 50
Expanding the Repertoire of Heterocycle Ring Pairs for Programmable Minor Groove DNA Recognition
Marques, M. A., Doss, R. M., Foister, S., & Dervan, P. B. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0486465 · Cited by 44
Ebp1 activates podoplanin expression and contributes to oral tumorigenesis
Mei, Y., Zhang, P., Zuo, H., Clark, D. J., Xia, R., Li, J., Liu, Z., & Mao, L. (2013) · Oncogene · doi:10.1038/onc.2013.354 · Cited by 45
Luo, J., Zhou, X., Ge, X., Liu, P., Cao, J., Lu, X., Ling, Y., & Zhang, S. (2013) · Cancer Science · doi:10.1111/cas.12248 · Cited by 46
Majumder, A., Banerjee, S., Harrill, J., Machacek, D. W., Mohamad, O., Bacanamwo, M., Mundy, W. R., Wei, L., Dhara, S. K., & Stice, S. L. (2012) · Stem Cells · doi:10.1002/stem.1201 · Cited by 48
Sensitization of Head and Neck Cancer to Cisplatin Through the Use of a Novel Curcumin Analog
Abuzeid, W. M., Davis, S. J., Tang, A. L., Saunders, L. M., Brenner, J. C., Lin, J., Fuchs, J. R., Light, E., Bradford, C. R., Prince, M. E., et al. (2011) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archoto.2011.63 · Cited by 48
“COMMENT Platinum-based compounds are often used as first-line agents in the treatment of HNSCC. Cisplatin exerts a dosedependent effect such that higher doses induce apoptosis in a larger fraction of tumor cells.28 The effectiveness of cisplatin is tempered by the development of enhanced DNA damage repair mechanisms i…”
BackgroundInfluentialLiu, X., Ouyang, L., Cai, X., Huang, Y., Feng, X., Fan, Q., & Huang, W. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.08.027 · Cited by 44
Yoo, S.-M., Lee, C., An, H., Lee, J. Y., Lee, H. S., Kang, H. C., Cho, S.-J., Kim, S. M., Park, J., Kim, D. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081994 · Cited by 43
“In the nucleus, transcription factors are eventually activated, resulting in the regulation of various cellular behaviors including cell proliferation, transformation, migration, and death [10].”
BackgroundEsser, A. K., Ross, M. H., Fontana, F., Su, X., Gabay, A. J., Fox, G. C., Xu, Y., Xiang, J., Schmieder, A. H., Yang, X., et al. (2020) · Theranostics · doi:10.7150/thno.44523 · Cited by 45
“Previous attempts at inhibiting MYC function have included anti-sense nucleic acid strategies [22], RNA interference [23], and interference with MYC-MAX dimerization and subsequent E-box binding using small molecules [24-32].”
BackgroundLi, D., Li, Y., Luo, F., Qiu, B., & Lin, Z. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03086 · Cited by 43
Targeting virulence to prevent infection: to kill or not to kill?
Alekshun, M. N., & Levy, S. B. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.10.006 · Cited by 45
Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors
Brotherton‐Pleiss, C., Yue, P., Zhu, Y., Nakamura, K., Chen, W., Fu, W., Kubota, C. S., Chen, J., Alonso-Valenteen, F., Mikhael, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01705 · Cited by 43
Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy
Sen, E. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.003 · Cited by 44
Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma
Yang, C., Hornicek, F. J., Wood, K. B., Schwab, J. H., Choy, E., Mankin, H., & Duan, Z. (2010) · Spine · doi:10.1097/brs.0b013e3181c2d2b4 · Cited by 42
“Stat3 is a cytoplasmic transcription factor, which is activated by cytokines and growth factor receptors, after its phosphorylation on tyrosine 705 by tyrosine kinases of the Janus tyrosine kinases (JAKs) and/or Src family, it dimerises and enters the nucleus where it induces the expression of target genes.(12,14,15)…”
BackgroundLin, J., Chen, Y., Cai, Q., Wei, L., Zhan, Y., Shen, A., Sferra, T. J., & Peng, J. (2013) · Integrative Cancer Therapies · doi:10.1177/1534735413508811 · Cited by 42
Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers
Roshan‐Moniri, M., Hsing, M., Butler, M. S., Cherkasov, A. R., & Rennie, P. S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.005 · Cited by 49
“Conventionally, targeting transcriptional factors has been a challenging task in drug discovery due to the lack of well-defined active sites [4].”
BackgroundCooper, C. D. O., Newman, J. A., & Gileadi, O. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130227 · Cited by 49
Hong, S.-H., Youbi, S. E., Hong, S. P., Kallakury, B., Monroe, P. J., Erkizan, H. V., Barber-Rotenberg, J. S., Houghton, P. J., Üren, A., & Toretsky, J. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1495 · Cited by 47
“Transcription factors have largely been considered ‘undruggable’ in general, given both their lack of enzymatic activity and intrinsically disordered domains that challenge crystallization [8].”
Nakamura, R., Tsukahara, T., Qü, W., Ichikawa, K., Otsuka, T., Ogoshi, K., Saito, T., Matsushima, K., Sugano, S., Hashimoto, S., et al. (2014) · Development · doi:10.1242/dev.108548 · Cited by 44
“The strict repression is important presumably because the derepression of those transcription factors would result in inappropriate cell differentiation (Boyer et al., 2006; Fujikura et al., 2002) or malignancies such as cancer (Darnell, 2002).”
BackgroundAquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3
Wang, Y., Wu, G., Fu, X., Xu, S., Wang, T., Zhang, Q., & Yang, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1712-0 · Cited by 42
Chen, X., Gao, F., Zhou, Z., Yang, W., Guo, L.-T., & Ji, L. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.01.010 · Cited by 42
Wang, L., Xu, Y., Li, F., Li, Y., & Lou, L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.004 · Cited by 42
Androgen Receptor as a Therapeutic Target for Androgen Independent Prostate Cancer
Sharifi, N., & Farrar, W. L. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200603000-00013 · Cited by 43
“One reason why transcription factors make attractive targets for cancer chemotherapy is precisely this feature—that they lie at the convergence of signaling pathways.(36) However, there are difficult problems intrinsic to making effective inhibitors of transcription factors such as the challenging task of finding smal…”
BackgroundTsiftsoglou, A. S., Bonovolias, I. D., & Tsiftsoglou, S. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.001 · Cited by 50
Couthier, A., Smith, J. A., McGarr, P., Craig, B. H., & Gilleard, J. S. (2003) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2003.10.012 · Cited by 43
“Keywords:Nematode;Haemonchus; Caenorhabditis; GATA; Transcription factor;elt-2; Endoderm”
Effects of anticancer drugs on transcription factor–DNA interactions
Gniazdowski, M., Denny, W. A., Nelson, S. M., & Czyz, M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.471 · Cited by 41
“A limited list of the transcription factors that are overactive in most human cancer cells has been recently published [89].”
BackgroundPast, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
Lorenzin, F., & Demichelis, F. (2022) · Cancers · doi:10.3390/cancers14051118 · Cited by 44
“Transcription factors have been thus far considered ‘undruggable’ because of the lack of easily targetable binding pockets and the complex and often poorly understood regulation and function of individual transcription factor domains [135,136].”
BackgroundZhang, L., Ye, D., Pan, H., Wei, K., Wang, L., Wang, X.-D., Shen, G.-F., & Zhang, Z. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.06.003 · Cited by 42
Mandal, P. K., Ren, Z., Chen, X., Xiong, C., & McMurray, J. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901105k · Cited by 44
“Substitution of C(2) of the ethyl group (C(4) of Aba) results in loss of activity, even those possessing benzyloxymethyl and benzylozyethyl groups, 36, and 37 respectively.”
BackgroundInfluentialZhao, M., Sun, J., & Zhao, Z. (2013) · Molecular BioSystems · doi:10.1039/c3mb70172g · Cited by 42
Porta, F., Facchetti, G., Ferri, N., Gelain, A., Meneghetti, F., Villa, S., Barlocco, D., Masciocchi, D., Asai, A., Miyoshi, N., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.017 · Cited by 43
“[710] Literature data highlighted that cisplatin, besides interacting with DNA, was able to modulate mitogen-activated protein kinase (MAPK) family and the phosphoinositide 3 (PI-3)-kinase/Akt pathway.[11, 12] Moreover, many platinum complexes displayed an effective inhibition of signal transducer and activator of tra…”
Xu, X.-L., Deng, S., Lian, Z., & Yu, K. (2021) · Antioxidants · doi:10.3390/antiox10111718 · Cited by 44
“ing dysregulated growth, survival, and angiogenesis as well as modulating immune responses [100,101].”
BackgroundRecent advances in field effect transistor biosensor technology for cancer detection: a mini review
Chao, L., Liang, Y. J., Hu, X., Shi, H., Xia, T., Zhang, H., & Xia, H. (2021) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/ac3f5a · Cited by 42
“Biomarkers are considered to be indicators of various diseases (including cancer, viral infections, and autoimmune diseases) [54, 55].”
BackgroundTranscriptional Switches: Chemical Approaches to Gene Regulation
Lee, L. W., & Mapp, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.075044 · Cited by 41
Crinelli, R., Bianchi, M., Gentilini, L., Palma, L., Sørensen, M. D., Bryld, T., Babu, R. B., Arar, K., Wengel, J., & Magnani, M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh503 · Cited by 41
Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells
Niida, A., Smith, A. D., Imoto, S., Tsutsumi, S., Aburatani, H., Zhang, M. Q., & Akiyama, T. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-404 · Cited by 43
“Background Deregulation of transcriptional programs leads to development and progression of cancer, and many transcription factors (TFs) have been identified as oncogenes or tumor suppressor genes [1].”
BackgroundCellular STAT3 Functions via PCBP2 To Restrain Epstein-Barr Virus Lytic Activation in B Lymphocytes
Koganti, S. R. K., Clark, C., Zhi, J., Li, X., Chen, E. I., Chakrabortty, S., Hill, E. R., & Bhaduri‐McIntosh, S. (2015) · Journal of Virology · doi:10.1128/jvi.00121-15 · Cited by 41
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies
Shahani, V. M., Yue, P., Haftchenary, S., Zhao, W. M., Lukkarila, J. L., Zhang, X., Ball, D. P., Nona, C. N., Gunning, P. T., & Turkson, J. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100224d · Cited by 41
RetractedMetal complexes as inhibitors of transcription factor activity
Leung, C., He, H., Liu, L., Wang, M., Chan, D. S., & Ma, D. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.08.008 · Cited by 41
Poli, G., Gelain, A., Porta, F., Asai, A., Martinelli, A., & Tuccinardi, T. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1079184 · Cited by 42
Li, H., Zhang, W., Niu, C., Lin, C., Wu, X., Jian, Y., Li, Y., Ye, L., Dai, Y., Ouyang, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32293 · Cited by 41
“Moreover, it there is evidence that transcription factors direct binding accessibility on DNA loci, and are overactive in most human cancer cells, which makes them promising targets for the development of anticancer drugs.(49,50) In our study, we demonstrate that NR2F6 serves as a transcription factor, directs binding…”
BackgroundGoel, S., Bhatia, V., Kundu, S., Biswas, T., Carskadon, S. L., Gupta, N. S., Asim, M., Morrissey, C. M., Palanisamy, N., & Ateeq, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25623-2 · Cited by 45
Tian, W., Li, B., Zhang, X., Dang, W., Wang, X., Tang, H., Wang, L., Cao, H., & Chen, T. (2012) · Oncology Reports · doi:10.3892/or.2012.1911 · Cited by 47
“Evidences supports that selectively suppressing constitutive Stat3 signaling is an effective approach in inhibiting cancer-associated processes and cancer progression (5,6).”
Mahato, R. K., Bhattacharya, S., Khullar, N., Sidhu, I. S., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.003 · Cited by 43
Chemical intervention of the NM23-H2 transcriptional programme onc-MYCvia a novel small molecule
Shan, C., Lin, J., Hou, J., Liu, H., Chen, S.-B., Chen, A.-C., Ou, T., Tan, J., Li, D., Gu, L., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv641 · Cited by 41
“In general, mutations in upstream regulators and aberrant gene amplification may destabilize the proper function of the transcription factor network and drive disease (7,8).”
BackgroundTranscription factors and chromatin proteins as therapeutic targets in cancer
Johnston, S. J., & Carroll, J. S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.02.002 · Cited by 52
Hypoxia‐Inducible Factor 1 Inhibitors
Melillo, G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35020-9 · Cited by 44
Pan, D., Pham, C. T. N., Weilbaecher, K. N., Tomasson, M. H., Wickline, S. A., & Lanza, G. M. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1355 · Cited by 40
Ferla-Brühl, K. L., Westhoff, M., Karl, S., Kasperczyk, H., Zwacka, R. M., Debatin, K., & Fulda, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209841 · Cited by 45
“As NF-kB has been reported to play an important role in regulation of apoptosis and chemoresistance in cancer (Darnell, 2002), there has been an increasing interest in the NF-kB pathway as a potential target for cancer therapy.”
BackgroundNew insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy
Zeng, L., Zhu, Y., Moreno, C. S., & Wan, Y. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.003 · Cited by 41
Rodríguez, J., Mosquera, J., Couceiro, J. R., Vázquez, M. E., & Mascarenas, J. L. (2015) · Chemical Science · doi:10.1039/c5sc01415h · Cited by 41
Wang, W., Xu, Y., Wang, Y.-H., Sun, H.-X., Sun, Y., He, Y., Zhu, Q.-F., Hu, B., Zhang, X., Xia, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17004 · Cited by 38
Targeting Transcription Factors in Cancer: From “Undruggable” to “Druggable”
Tao, Z., & Wu, X. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2815-7_9 · Cited by 43
Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors
Ahmad, A., Rashid, S., Chaudhary, A. A., Alawam, A. S., Alghonaim, M. I., Raza, S. S., & Khan, R. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.002 · Cited by 40
Zhu, D., Wang, L., Xu, X., & Jiang, W. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.08.034 · Cited by 37
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 41
“Yet, because of the absence of a clear ligand-binding domain and its unstructured nature, direct targeting of MYC is still a challenge [124,125].”
BackgroundNovel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors
Pallandre, J., Borg, C., Rognan, D., Boibessot, T., Luzet, V., Yesylevskyy, S. O., Ramseyer, C., & Pudlo, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.054 · Cited by 38
Li, B. X., Yamanaka, K., & Xiao, X. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.056 · Cited by 41
Overexpression of phosphorylated‐ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma
Chen, S., Takeuchi, S., Urabe, K., Hayashida, S., Makiko, K. I. D. O., Tomoeda, H., Uchi, H., Dainichi, T., Takahara, M., Shibata, S., et al. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2007.00887.x · Cited by 39
LRP16 Integrates into NF-κB Transcriptional Complex and Is Required for Its Functional Activation
Wu, Z., Li, Y., Li, X., Ti, D., Zhao, Y., Si, Y., Mei, Q., Zhao, P., Fu, X., & Han, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018157 · Cited by 40
“To date, NF-kB and the signaling pathways involved in its activation are considered the most attractive targets for cancer prevention and therapy [8].”
BackgroundLi, T., Liu, X., Qian, H., Zhang, S., Hou, Y., Zhang, Y., Luo, G., Zhu, X., Tao, Y., Fan, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51197-w · Cited by 38
Fitzgerald, K. A., Evans, J. C., McCarthy, J., Guo, J., Prencipe, M., Kearney, M., Watson, R. W. G., & O’Driscoll, C. M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.896904 · Cited by 37
“They offer an exciting therapeutic target in the treatment of cancer because one transcription factor can be involved downstream of several potentially oncogenic pathways and thus targeting one transcription factor successfully may combat various upstream oncogenes [37].”
Gene regulatory networks by transcription factors and microRNAs in breast cancer
Qin, S., Ma, F., & Chen, L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu597 · Cited by 37
Liang, S., Zhang, X., & Wang, G. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.03.066 · Cited by 36
Stelma, T., & Leaner, V. D. (2017) · Oncotarget · doi:10.18632/oncotarget.15834 · Cited by 41
“Darnell (2002) proposed that inhibiting nuclear import proteins may be a way of specifically targeting multiple overactive transcription factors [57].”
BackgroundLi, B., Shao, Z., & Chen, Y. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338478 · Cited by 35
Zhou, X., Yuan, Y., Kuang, H., Bingxiang, T., Zhang, H., & Zhang, M. (2022) · Bioengineered · doi:10.1080/21655979.2021.2013108 · Cited by 35
“Transcription factors (TFs) are proteins that regulate tumor progression by promoting or inhibiting downstream genes [16] [17].”
BackgroundSammak, S., & Zinzalla, G. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.004 · Cited by 43
Mesa, R. A., Tefferi, A., Lasho, T., Loegering, D. A., McClure, R. F., Powell, H. L., Dai, N. T., Steensma, D. P., & Kaufmann, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404338 · Cited by 38
DNA vaccines suppress tumor growth and metastases by the induction of anti‐angiogenesis
Reisfeld, R. A., Niethammer, A. G., Luo, Y., & Xiang, R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00137.x · Cited by 36
“Firstly, a limited number of transcription factors are generally overactive in most cancer cells, which makes them appropriate targets for anti-cancer drugs, provided selective inhibition of transcription can be applied rather than general inhibition, which is expected to be too toxic (38).”
BackgroundAssociation and nuclear translocation of PIAS3-STAT3 complex is ligand and time dependent
Dabir, S., Kluge, A., & Dowlati, A. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0313 · Cited by 39
Auzenne, E. J., Klostergaard, J., Mandal, P. K., Liao, W. S. ‐., Lü, Z., Gao, F., Bast, R. C., Robertson, F. M., & McMurray, J. S. (2012) · PubMed · Cited by 47
Pichler, A., Prior, J. L., Luker, G. D., & Piwnica-Worms, D. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801075105 · Cited by 35
“In vivo transfection of mouse hepatocytes was performed using the hydrodynamic somatic gene transfer method as described (3, 5).”
BackgroundMethodWang, J., Zhang, L., Chen, G., Zhang, J., Li, Z., Lü, W., Liu, M., & Pang, X. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3165-6 · Cited by 37
Bernaciak, T. M., Zareno, J., Parsons, J. T., & Silva, C. M. (2009) · Breast Cancer Research · doi:10.1186/bcr2341 · Cited by 38
“Many tumorigenic signaling pathways converge on common nuclear transcription factors, and therefore, targeting these downstream proteins may be more effective [1].”
BackgroundA Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors
Gayvert, K. M., Dardenne, É., Cheung, C., Boland, M. R., Lorberbaum, T., Wanjala, J., Chen, Y., Rubin, M. A., Tatonetti, N. P., Rickman, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.037 · Cited by 37
Compound Shape Effects in Minor Groove Binding Affinity and Specificity for Mixed Sequence DNA
Guo, P., Farahat, A. A., Paul, A., Harika, N. K., Boykin, D. W., & Wilson, W. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08152 · Cited by 36
Cancer and SOX proteins: New insight into their role in ovarian cancer progression/inhibition
Ashrafizadeh, M., Taeb, S., Hushmandi, K., Orouei, S., Shahinozzaman, M., Zabolian, A., Moghadam, E. R., Raei, M., Zarrabi, A., Khan, H. Z., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105159 · Cited by 36
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.